{"id":538351,"date":"2021-04-13T19:32:02","date_gmt":"2021-04-13T19:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538351"},"modified":"2021-04-13T19:32:02","modified_gmt":"2021-04-13T19:32:02","slug":"post-menopausal-osteoporosis-market-industry-analysis-key-companies-pipeline-therapies-epidemiology-and-market-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/post-menopausal-osteoporosis-market-industry-analysis-key-companies-pipeline-therapies-epidemiology-and-market-forecast-by-delveinsight_538351.html","title":{"rendered":"Post Menopausal Osteoporosis Market: Industry Analysis, Key Companies, Pipeline Therapies, Epidemiology and Market Forecast by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Post Menopausal Osteoporosis Market: Industry Analysis, Key Companies, Pipeline Therapies, Epidemiology and Market Forecast by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Post Menopausal Osteoporosis Market: Industry Analysis, Key Companies, Pipeline Therapies, Epidemiology and Market Forecast by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Post Menopausal Osteoporosis Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Post Menopausal Osteoporosis Market<\/a> Insights, Epidemiology, and Market Forecast-2030&#8243;<\/strong>&nbsp;report delivers an in-depth understanding of the Post Menopausal Osteoporosis, historical and forecasted epidemiology as well as the Post Menopausal Osteoporosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Osteoporosis<\/strong> is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis is of two different types, primary and secondary.<\/p>\n<p style=\"text-align: justify;\">Primary Osteoporosis is linked to the normal aging process. It can be further divided into &ldquo;primary type I&rdquo; and &ldquo;primary type II&rdquo; osteoporosis. Type I is generally referred to as postmenopausal osteoporosis (PMO), as it is more commonly seen among women (six times more frequent) who have gone through menopause, resulting in a drop in levels of estrogen. Primary type I osteoporosis occurs in women about 10 to 15 years after menopause, usually between the ages of 50 and 70. Type II osteoporosis (also known as senile), commonly caused by a long term calcium deficiency. Women are twice as more likely than men to suffer from<\/p>\n<p style=\"text-align: justify;\">Type II osteoporosis. Secondary Osteoporosis develops when certain medical conditions and medications increase bone remodeling leading to disruption of bone reformation.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Free Sample copy @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Post Menopausal Osteoporosis Report Facts:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total diagnosed prevalent population of osteoporosis in the seven major markets was found to be 28,097,783 cases in 2017. While, the total diagnosed prevalent population of osteoporosis in the United States was found to be 6,380,754 cases in 2017, which is expected to increase by 2030.<\/li>\n<li>Tian et al. conducted a study titled &ldquo;Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men&rdquo; wherein, the reported prevalence of osteoporosis in women was 9% in the United Kingdom, 15% in France and Germany, 16% in USA, and 38% in Japan. The prevalence of osteoporosis in the whole participants was 9.65% for postmenopausal women and 8.08% for elderly men.<\/li>\n<li>In the EU5 countries the total diagnosed prevalent population of osteoporosis was found to be maximum in Germany with 4,309,667 cases, followed by Italy with 3,840,703 cases in 2017. While, France had the lowest number of diagnosed prevalent cases of osteoporosis with 2,786,944 cases in 2017.<\/li>\n<li>A poster presented by the American Association of Clinical Endocrinologists stated that women with hip fracture have an increased mortality of 12% to 20% during the subsequent two years. More than 50% of hip fracture survivors are unable to return to independent living. More than 2 million osteoporosis-related fractures occur each year in the United States, and more than 70% of these occur in women. More than 20% of postmenopausal women have prevalent vertebral fractures.<\/li>\n<li>According to a study conducted by Sessa titled &ldquo;Clinical guidelines for the prevention and treatment of osteoporosis from the Italian Society for Orthopaedics and Traumatology: preface&rdquo; stated that in Italy, osteoporosis potentially affects about 5,000,000 people, of whom 80% are women of post-menopausal age.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get Free Sample copy @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Post Menopausal Osteoporosis Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Sandoz<\/li>\n<li>Haoma Medica<\/li>\n<li>Amgen Inc.<\/li>\n<li>Clonz Biotech<\/li>\n<li>Eli Lilly and Company,<\/li>\n<li>Enteris BioPharma<\/li>\n<li>Ligand Pharmaceuticals Incorporated.<\/li>\n<li>Merck &amp; Co., Inc<\/li>\n<li>Outlook Therapeutics, Inc<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Post Menopausal Osteoporosis Therapies<\/a> covered in the report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Denosumab (GP2411)<\/li>\n<li>NaQuinate<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed Post Menopausal Osteoporosis Therapies @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/post-menopausal-osteoporosis-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Post Menopausal Osteoporosis<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Post Menopausal Osteoporosis<\/p>\n<p style=\"text-align: justify;\">4. Post Menopausal Osteoporosis: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Post Menopausal Osteoporosis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Post Menopausal Osteoporosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Post Menopausal Osteoporosis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Post Menopausal Osteoporosis: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Post Menopausal Osteoporosis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=post-menopausal-osteoporosis-market-industry-analysis-key-companies-pipeline-therapies-epidemiology-and-market-forecast-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/post-menopausal-osteoporosis-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=post-menopausal-osteoporosis-market-industry-analysis-key-companies-pipeline-therapies-epidemiology-and-market-forecast-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Post Menopausal Osteoporosis Market DelveInsight&#8217;s &#8220;Post Menopausal Osteoporosis Market Insights, Epidemiology, and Market Forecast-2030&#8243;&nbsp;report delivers an in-depth understanding of the Post Menopausal Osteoporosis, historical and forecasted epidemiology as well as the Post Menopausal Osteoporosis market trends in the United States, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/post-menopausal-osteoporosis-market-industry-analysis-key-companies-pipeline-therapies-epidemiology-and-market-forecast-by-delveinsight_538351.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-538351","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538351"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538351\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}